Artículos por temáticas

Clinical pharmacology of novel anti-Alzheimer disease modifying medications

Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, Salomone S.

Curr Top Med Chem. 2013;13(15):1853-63. doi: 10.2174/15680266113139990141.

[Alzheimer's disease and genetics]

Rongve A, Årsland D, Graff C.

Tidsskr Nor Laegeforen. 2013 Aug 6;133(14):1449-52. doi: 10.4045/tidsskr.12.0873.

Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes

Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ, Masters CL.

Biomark Med. 2013 Aug;7(4):641-62. doi: 10.2217/bmm.13.59.

Imaging markers for Alzheimer disease: which vs how

Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johns

Neurology. 2013 Jul 30;81(5):487-500. doi: 10.1212/WNL.0b013e31829d86e8.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Sem

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D.

Food Chem Toxicol. 2013 Nov;61:209-14. doi: 10.1016/j.fct.2013.07.013. Epub 2013 Jul 16.

Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis

Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G.

Neurobiol Dis. 2013 Nov;59:100-10. doi: 10.1016/j.nbd.2013.07.005. Epub 2013 Jul 15.

Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma

Inoue T, Kawaji T, Tanihara H.

Invest Ophthalmol Vis Sci. 2013 Aug 9;54(8):5353-8. doi: 10.1167/iovs.13-12245.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11.

Is there a causal link between inflammation and dementia?

Enciu AM, Popescu BO.

Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.

2013 Alzheimer Award

J Alzheimers Dis. 2013;36(3):413-4. doi: 10.3233/JAD-139903.

Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease

Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, Van Eldik LJ, Bain LJ, Budd S.

Alzheimers Dement. 2013 Jul;9(4):452-458.e1. doi: 10.1016/j.jalz.2013.01.017.

Military risk factors for Alzheimer's disease

Weiner MW, Friedl KE, Pacifico A, Chapman JC, Jaffee MS, Little DM, Manley GT, McKee A, Petersen RC, Pitman RK, Yaffe K, Zetterberg H, Obana R, Bain LJ, Carrillo MC.

Alzheimers Dement. 2013 Jul;9(4):445-51. doi: 10.1016/j.jalz.2013.03.005.

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, F

Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.

Fluid biomarkers in Alzheimer's disease - current concepts

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20.